Search

Your search keyword '"Molina Arriero G"' showing total 15 results
Start Over Author "Molina Arriero G"
15 results on '"Molina Arriero G"'

1. DOP80 Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry

Author

Chaparro, M, primary, García Donday, M, additional, Núñez Ortiz, A, additional, Calviño Suarez, C, additional, Rubio Iturria, S, additional, Sánchez Azofra, M, additional, Calvo Moya, M, additional, Pérez-Martínez, I, additional, Fernández-Clotet, A, additional, Alfambra, E, additional, Marín Pedrosa, S, additional, Diz-Lois Palomares, M T, additional, Hernandez, V, additional, Ruiz-Cerulla, A, additional, Casanova, M J, additional, Rivero, M, additional, Huguet, J M, additional, Vicente Lidón, R, additional, Árias García, L, additional, Guerra, I, additional, Hervías Cruz, D, additional, Gutiérrez Casbas, A, additional, Bejarano, A, additional, Camargo Camero, R, additional, Rodríguez-Lago, I, additional, Aguas, M, additional, De Jorge Turrión, M Á, additional, Masedo Gonzalez, Á, additional, López Serrano, P, additional, Valldosera Gomis, G, additional, Ceballos, D, additional, Bujanda, L, additional, Molina Arriero, G, additional, Vega Villaamil, P, additional, Van Domselaar, M, additional, Boscá Watts, M M, additional, Lucendo, A J, additional, Zúñiga de Mora-Figueroa, B, additional, Busquets, D, additional, and Gisbert, J P, additional

Published
2024
Full Text
View/download PDF

4. P949 Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study. A multicenter study from the young group of GETECCU

Author

Fuentes-Valenzuela, E, primary, Bastón-Rey, I, additional, García-Alonso, F J, additional, Leo Carnerero, E, additional, Garcia de la Filia, I, additional, Pedraza Pérez, A, additional, Sáiz Chumillas, R M, additional, Pascual Oliver, A, additional, Muñoz Villafranca, C, additional, Moreno, V, additional, Suárez Ferrer, C, additional, Molina Arriero, G, additional, Ferreiro-Iglesias, R, additional, Vega Villaamil, P, additional, Gardeazábal Mateos, D, additional, Segarra-Ortega, J X, additional, Garrido Marín, A, additional, Doallo, A I, additional, Elosua, A, additional, Alonso-Galán, H, additional, Brunet- Mas, E, additional, Jimenez García, N, additional, López Romero-Salazar, F, additional, Velayos, B, additional, Carballo-Folgoso, L, additional, Pérez Santamaría, C, additional, Mata Román, L, additional, Núñez Ortiz, A, additional, Barrio, J, additional, Barreiro-de Acosta, M, additional, and Gutiérrez-Casbas, A, additional

Published
2024
Full Text
View/download PDF

5. P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding

Author

Chaparro, M, primary, García Donday, M, additional, Rubio, S, additional, Calviño Suarez, C, additional, Nuñez Ortiz, A, additional, Figueira, M, additional, Marín Pedrosa, S, additional, Rivero, M, additional, Fernández-Clotet, A, additional, Madero, L, additional, Diz-Lois Palomares, M T, additional, Pérez-Martínez, I, additional, Ruiz-Cerulla, A, additional, Arroyo, M, additional, Piqueras, M, additional, Suarez Ferrer, C, additional, Aguas, M, additional, Calvo Moya, M, additional, Guerra, I, additional, López Serrano, P, additional, Vázquez Morón, J M, additional, Arias García, L, additional, Casanova, M J, additional, Huguet, J M, additional, Valldosera Gomis, G, additional, Zúñiga de Mora-Figueroa, B, additional, Armesto, R, additional, Martínez Montiel, P, additional, Rodríguez-Lago, I, additional, Sendra Rumbeu, P, additional, Camargo Camero, R, additional, Hervías Cruz, D, additional, Molina Arriero, G, additional, Barreiro-de Acosta, M, additional, Acosta, D, additional, Brenes, Y, additional, Hermida, S, additional, Parra, P, additional, Garre, A, additional, and Gisbert, J P, additional

Published
2023
Full Text
View/download PDF

7. P550 Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU

Author

Chaparro, M, primary, Donday, M G, additional, Rubio, S, additional, Nuñez, A, additional, Calviño Suarez, C, additional, Madero, L, additional, Figueira, M, additional, Rivero, M, additional, Pérez Martínez, I, additional, Diz-Lois Palomares, M T, additional, Huguet, J M, additional, Marín Pedrosa, S, additional, Aguas, M, additional, Arroyo, M, additional, Ruiz-Cerulla, A, additional, Vázquez Morón, J M, additional, Fernández-Clotet, A, additional, Guerra, I, additional, López Serrano, P, additional, Rodríguez-Lago, I, additional, Arias García, L, additional, Camargo Camero, R, additional, Casanova, M J, additional, Martínez Montiel, P, additional, Sendra Rumbeu, P, additional, Suarez Ferrer, C, additional, Valldosera Gomis, G, additional, Armesto, R, additional, Bujanda, L, additional, Calvo Moya, M, additional, Hervías Cruz, D, additional, Robles Alonso, V, additional, de Jorge Turrión, M Á, additional, Zúñiga de Mora-Figueroa, B, additional, Molina Arriero, G, additional, Acosta, D, additional, Brenes, Y, additional, Hermida, S, additional, Parra, P, additional, and Gisbert, J P, additional

Published
2022
Full Text
View/download PDF

8. DOP52 Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry)

Author

Chaparro, M, primary, García Donday, M, additional, Calviño Suarez, C, additional, Rubio, S, additional, Figueira, M, additional, Pérez Martínez, I, additional, Leo Carnerero, E, additional, Rodríguez Lago, I, additional, Ruiz Cerulla, A, additional, Aguas, M, additional, López Serrano, P, additional, Ramírez de la Piscina Urraca, P, additional, Rivero, M, additional, Suarez Ferrer, C, additional, Alfambra Cabrejas, E, additional, Armesto, R, additional, Diz-Lois Palomares, M T, additional, Guerra, I, additional, Vázquez Morón, J M, additional, Casanova, M J, additional, Hervías Cruz, D, additional, Huguet, J M, additional, de Jorge Turrión, M Á, additional, Marín Pedrosa, S, additional, Molina Arriero, G, additional, Ramos, L, additional, Zúñiga de Mora-Figueroa, B, additional, Camargo Camero, R, additional, Fernández-Clotet, A, additional, Gutiérrez Casbas, A, additional, Martínez Montiel, P, additional, Rodríguez Insa, R, additional, Sendra Rumbeu, P, additional, Tardillo Marín, C, additional, Vicente Lidón, R, additional, Arias García, L, additional, Bujanda, L, additional, Lucendo, A J, additional, Manceñido Marcos, N, additional, and Gisbert, J P, additional

Published
2021
Full Text
View/download PDF

10. P152 Should professionals provide their patients with digital health training resources?

Author

Echarri Piudo, A, primary, Molina Arriero, G, additional, Sierra Ausin, M, additional, Calvo Moya, M, additional, Pérez Calle, J L, additional, Fraga Iriso, R, additional, Morete Pérez, M C, additional, Botella Mateu, B, additional, Ollero Pena, V, additional, Enriquez Rodriguez, M, additional, Nos Mateu, P, additional, Castro Senosiain, B, additional, Martín Rodriguez, D, additional, and Mancenido Marcos, N, additional

Published
2020
Full Text
View/download PDF

13. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.

Author

Chaparro M, Baston-Rey I, Fernández-Salgado E, González García J, Ramos L, Diz-Lois Palomares MT, Argüelles-Arias F, Iglesias Flores E, Cabello M, Rubio Iturria S, Núñez Ortiz A, Charro M, Ginard D, Dueñas Sadornil C, Merino Ochoa O, Busquets D, Iyo E, Gutiérrez Casbas A, Ramírez de la Piscina P, Boscá-Watts MM, Arroyo M, García MJ, Hinojosa E, Gordillo J, Martínez Montiel P, Velayos Jiménez B, Quílez Ivorra C, Vázquez Morón JM, María Huguet J, González-Lama Y, Muñagorri Santos AI, Amo VM, Martín-Arranz MD, Bermejo F, Martínez Cadilla J, Rubín de Célix C, Fradejas Salazar P, San Román AL, Jiménez N, García López S, Figuerola A, Jiménez I, Martínez Cerezo FJ, Taxonera C, Varela P, de Francisco R, Monfort D, Molina Arriero G, Hernández Camba A, García-Alonso FJ, Van Domselaar M, Pajares Villarroya R, Núñez A, Rodríguez Moranta F, Marín-Jiménez I, Robles Alonso V, Martín Rodríguez MDM, Camo-Monterde P, García Tercero I, Navarro Llavat M, Arias García L, Hervías Cruz D, Sulleiro S, Novella C, Vispo E, Barreiro-de Acosta M, and Gisbert JP

Subjects
Humans, Retrospective Studies, Remission Induction, Immunosuppressive Agents therapeutic use, Treatment Outcome, Ustekinumab therapeutic use, Crohn Disease drug therapy
Abstract

Background: Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn's disease (CD) patients in real-world clinical practice., Methods: A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety., Results: A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologic therapy, 141 (30.5%) of whom had received ≥3 agents. In addition, 35.2% received concomitant immunosuppressants, and 47.1% had ≥1 abdominal surgery. At week 16, 56% had remission, 70% had response, and 26.1% required dose escalation or intensification; of these, 24.8% did not subsequently reduce dose. After a median follow-up of 15 months, 356 (77%) patients continued treatment. The incidence rate of ustekinumab discontinuation was 18% per patient-year of follow-up. Previous intestinal surgery and concomitant steroid treatment were associated with higher risk of ustekinumab discontinuation, while a maintenance schedule every 12 weeks had a lower risk; neither concomitant immunosuppressants nor the number of previous biologics were associated with ustekinumab discontinuation risk. Fifty adverse events were reported in 39 (8.4%) patients; 4 of them were severe (2 infections, 1 malignancy, and 1 fever)., Conclusions: Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice., (© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)

Published
2022
Full Text
View/download PDF

14. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.

Author

Chaparro M, Baston-Rey I, Fernández Salgado E, González García J, Ramos L, Diz-Lois Palomares MT, Argüelles-Arias F, Iglesias Flores E, Cabello M, Rubio Iturria S, Núñez Ortiz A, Charro M, Ginard D, Dueñas Sadornil C, Merino Ochoa O, Busquets D, Iyo E, Gutiérrez Casbas A, Ramírez de la Piscina P, Boscá-Watts MM, Arroyo M, García MJ, Hinojosa E, Gordillo J, Martínez Montiel P, Velayos Jiménez B, Quílez Ivorra C, Vázquez Morón JM, Huguet JM, González-Lama Y, Muñagorri Santos AI, Amo VM, Martín Arranz MD, Bermejo F, Martínez Cadilla J, Rubín de Célix C, Fradejas Salazar P, López San Román A, Jiménez N, García-López S, Figuerola A, Jiménez I, Martínez Cerezo FJ, Taxonera C, Varela P, de Francisco R, Monfort D, Molina Arriero G, Hernández-Camba A, García Alonso FJ, Van Domselaar M, Pajares-Villarroya R, Núñez A, Rodríguez Moranta F, Marín-Jiménez I, Robles Alonso V, Martín Rodríguez MDM, Camo-Monterde P, García Tercero I, Navarro-Llavat M, García LA, Hervías Cruz D, Kloss S, Passey A, Novella C, Vispo E, Barreiro-de Acosta M, and Gisbert JP

Abstract

Ustekinumab has shown efficacy in Crohn's Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. The objective of this analysis was to determine whether baseline patient characteristics are predictive of remission and the drug durability of ustekinumab, and whether its positioning with respect to prior use of biologics has a significant effect after correcting for disease severity and phenotype at baseline using interpretable machine learning. Patients' data from SUSTAIN, a retrospective multicenter single-arm cohort study, were used. Disease phenotype, baseline laboratory data, and prior treatment characteristics were documented. Clinical remission was defined as the Harvey Bradshaw Index ≤ 4 and was tracked longitudinally. Drug durability was defined as the time until a patient discontinued treatment. A total of 439 participants from 60 centers were included and a total of 20 baseline covariates considered. Less exposure to previous biologics had a positive effect on remission, even after controlling for baseline disease severity using a non-linear, additive, multivariable model. Additionally, age, body mass index, and fecal calprotectin at baseline were found to be statistically significant as independent negative risk factors for both remission and drug survival, with further risk factors identified for remission.

Published
2022
Full Text
View/download PDF

15. Colonic ulcer as an uncommon finding of mastocytosis.

Author

Pradera Cibreiro C, Ramos Alonso M, Vázquez Bueno JÁ, and Molina Arriero G

Subjects
Aged, 80 and over, Colonoscopy, Humans, Male, Tomography, X-Ray Computed, Colonic Diseases diagnostic imaging, Colonic Diseases pathology, Mastocytosis diagnostic imaging, Mastocytosis pathology, Ulcer diagnostic imaging, Ulcer pathology
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results